Core Viewpoint - The stock of Suzhou Fengbei Biotechnology Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days on February 4 and 5, 2026, prompting a review of the situation by the company [2][4]. Group 1: Stock Trading Abnormality - The company's stock price showed a significant deviation, with a cumulative increase of over 20% on February 4 and 5, 2026, classified as an abnormal trading fluctuation according to the Shanghai Stock Exchange rules [2][4]. - The company conducted a self-examination and confirmed that there were no undisclosed significant matters apart from those already disclosed [2][6]. Group 2: Operational Status - The company reported that its production and operational activities are normal, with no significant changes in market conditions or industry policies, and no substantial fluctuations in production costs or sales [5]. - There are no major undisclosed matters involving the company, including significant asset restructuring, share issuance, acquisitions, or other major corporate actions [6]. Group 3: Media and Market Rumors - The company found no media reports, market rumors, or trending concepts that could significantly impact its stock price during the abnormal trading period [7]. - Company executives and major shareholders did not engage in buying or selling the company's stock during the period of abnormal trading fluctuations [8].
苏州丰倍生物科技股份有限公司 股票交易异常波动公告